In a report published Monday, Morgan Stanley analyst Dara Mohsenian reiterated an Overweight rating on Colgate-Palmolive Company CL, and raised the price target from $70.00 to $73.00.
In the report, Morgan Stanley noted, “CL Q1 EPS was in-line with consensus, with sales, gross, and oper. profit all within 1% of consensus. Organic sales growth was strong at +6.5%, above the 5.9% consensus, with two-yr avg. growth of +6.3% above +5.5% in H2 of 2013. Pricing was solid at +1.5%, sequentially improving from a flat Q4 result. However, gross margins were 50 bps below consensus (confirming our concerns that CL's prior guidance was too high), leading to in-line profit. Emerging markets organic sales growth of +10% was strong on a y-o-y/2-yr avg. basis, both in line with 2013, although CL indicated EM category growth slowed to 5-7% from 6-8%. Post-strong Q1 EPS, we are raising our EPS by 1% (1% above CL guidance) and our price target by 4% to $73. We remain OW with stronger CL organic sales growth and FX neutral EPS growth than peers. We believe CL offers investors a solid low-teens annual return with 11% long-term FX neutral EPS growth and a 2% div. yield, but do not expect multiple expansion with CL's 16% P/E premium vs. peers.”
Colgate-Palmolive Company closed on Friday at $66.24.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in